Clinical trials: Immune System Disease
Diffuse Large B-Cell Lymphoma
A Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Antitumor Activity of Loncastuximab Tesirine in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated Diffuse Large B-cell Lymphoma (LOTIS-8)
The primary objective of this study is to characterize the safety and tolerability of loncastuximab tesirine in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) chemotherapy, and…
- Trial name
- LOTIS-8 (NCT04974996)
- Testing
- Loncastuximab tesirine, Prednisone, Rituximab
- Where
- United States
- Sponsor
- ADC Therapeutics S.A.
Carcinoma, Midline
A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK525762 in Subjects With NUT Midline Carcinoma (NMC) and Other Cancers
This study is divided into two parts; Part 1 of the study is a dose escalation phase to select the recommended dose for Part 2 based on the safety, pharmacokinetic, and pharmacodynamic profiles observed after oral administration…
- Trial name
- NCT01587703
- Testing
- GSK525762
- Where
- 17 sites in United States, Australia and 5 more
- Volunteers
- 196 people
- Sponsor
- GlaxoSmithKline
Diabetes, Diabetes Mellitus, Type 1
A Non-interventional, Post Marketing Surveillance (PMS) Study of Tresiba® (Insulin Degludec) to Evaluate Long Term Safety and Efficacy in Patients With Diabetes Mellitus in Routine Clinical Practice in India
This study is conducted in Asia. The aim of the study is to evaluate long term safety and efficacy of Tresiba® (insulin degludec) in patients with diabetes mellitus in routine clinical practice in India.
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- NCT02117622
- Testing
- insulin degludec
- Where
- 38 sites in India
- Volunteers
- 1,056 people
- Sponsor
- Novo Nordisk A/S
Osteoarthritis, Hip, Rheumatoid Arthritis
Exception Cementless Hip Stem
This study is a multicenter, retrospective and prospective, non-controlled, non-randomized post market clinical follow-up study.
- Conditions
- Osteoarthritis, Hip, Rheumatoid Arthritis, Inflammatory Arthritis, Congenital Hip Dysplasia
- Trial name
- Exception (NCT04349046)
- Testing
- Total hip arthoplasty (THA)
- Where
- 6 sites in Belgium, France
- Volunteers
- 332 people
- Sponsor
- Zimmer Biomet
Follicular Lymphoma
A Study Evaluating the Safety and Efficacy of Venetoclax (GDC-0199) Plus Bendamustine + Rituximab (BR) in Comparison With BR or Venetoclax Plus Rituximab in Participants With Relapsed and Refractory Follicular Non-Hodgkin's Lymphoma (fNHL)
This open-label, international, multicenter study will investigate the safety and efficacy of venetoclax (GDC-0199) in combination with bendamustine plus rituximab (venetoclax + BR) compared with BR alone in participants with…
- Trial name
- NCT02187861
- Testing
- Venetoclax, Bendamustine, Rituximab
- Where
- 71 sites in United States, Australia and 6 more
- Volunteers
- 163 people
- Sponsor
- Hoffmann-La Roche
Lymphoma
A Phase 1 Study Evaluating CPI-0610 in Patients With Progressive Lymphoma
First in human, open-label, sequential dose escalation and expansion study of CPI-0610 in patients with progressive lymphoma. CPI-0610 is a small molecule inhibitor of bromodomain and extra-terminal (BET) proteins.
- Trial name
- NCT01949883
- Testing
- CPI-0610
- Volunteers
- 64 people
- Sponsor
- Constellation Pharmaceuticals
Asthma
Efficacy of FLUTIFORM ® vs Seretide® in Moderate to Severe Persistent Asthma in Subjects Aged ≥12 Years
A double blind, double dummy, randomised, multicentre, two arm parallel group study to assess the efficacy and safety of FLUTIFORM® pMDI (2 puffs bid) vs Seretide® pMDI (2 puffs bid) in subjects aged ≥12 years with moderate to…
- Trial name
- NCT03387241
- Testing
- Fluticasone/ Formoterol, fluticasone/ salmeterol
- Where
- China
- Volunteers
- 330 people
- Sponsor
- Mundipharma (China) Pharmaceutical Co. Ltd
Atopic Dermatitis Eczema, Atopic Dermatitis
Trends in the Epidemiology and Treatment of Atopic Dermatitis in the United Kingdom (UK)
Atopic dermatitis (AD), commonly called eczema, is one of the most frequently occurring skin conditions. It is estimated to affect around one fifth of children in developed countries and is also becoming increasingly common in…
- Conditions
- Atopic Dermatitis Eczema, Atopic Dermatitis, Eczema
- Trial name
- NCT03823794
- Testing
- No intervention
- Where
- United Kingdom
- Volunteers
- 148,166 people, healthy volunteers welcome
- Sponsor
- Momentum Data
Lymphoma
BAY 59-8862 in Treating Patients With Refractory Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of BAY 59-8862 in treating patients who have refractory…
- Trial name
- NCT00039156
- Testing
- ortataxel
- Where
- 15 sites in United States, Canada
- Sponsor
- Theradex
Relapsing Remitting Multiple Sclerosis
Treatment Interruption of Natalizumab
This is a randomized, rater blinded trial in patients who interrupt treatment with natalizumab with or without being treated with other immunomodulatory drugs, or continue treatment with natalizumab.
- Trial name
- RESTORE (NCT01071083)
- Testing
- natalizumab, interferon beta 1-a, methylprednisolone
- Where
- 33 sites in United States, Germany and 1 more
- Volunteers
- 175 people
- Sponsor
- Biogen
Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia
Study of AQ4N in Patients With Non Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, or Small Lymphocytic Leukemia
The purpose of this study is to find answers to the following questions: What is the largest dose of AQ4N that can be given safely one time every three weeks for 24 weeks? What are the side effects of AQ4N when given according to…
- Conditions
- Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia
- Trial name
- NCT00109356
- Testing
- AQ4N (Chemotherapy)
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- Novacea
Immune Thrombocytopenia (ITP), Warm Autoimmune Hemolytic Anemia (WAIHA)
A Phase 1b/2a Study of Velinotamig in Adults With Relapsed/Refractory ITP and wAIHA
A Phase 1b/2a, open-label dose escalation and dose expansion study of subcutaneously (SC) administered velinotamig for the treatment of adults with relapsing and refractory immune thrombocytopenia (ITP) and warm autoimmune…
- Trial name
- NCT07738822
- Testing
- Velinotamig specified dose on specified days.
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- Cullinan Therapeutics Inc.
Multiple Myeloma
A Study of ATN-224 and Bortezomib in Patients With Multiple Myeloma
The purpose of this study is to describe the safety and effect of ATN-224 in combination with bortezomib (Velcade®) in patients with Multiple Myeloma who are relapsed from or refractory to bortezomib.
- Trial name
- NCT00352742
- Testing
- ATN-224 + bortezomib
- Where
- 10 sites in United States
- Volunteers
- 46 people
- Sponsor
- Attenuon
Multiple Myeloma, Myeloma
FT576 in Subjects With Multiple Myeloma
This is a Phase I dose-finding study of FT576 as monotherapy and in combination with the monoclonal antibody daratumumab in multiple myeloma (MM). The study will consist of a dose-escalation stage and an expansion stage.
- Trial name
- NCT05182073
- Testing
- FT576 (Allogenic CAR NK cells with BCMA expression), Cyclophosphamide, Fludarabine
- Where
- 14 sites in United States
- Volunteers
- 31 people
- Sponsor
- Fate Therapeutics
Multiple Sclerosis
Medication Usage and Patient Reported Outcomes Evaluation Via myBETAapp in Patients With Multiple Sclerosis Treated With Betaferon: a Pilot Study
The planned study will be a prospective, non-interventional, observational cohort study using the structure of a registry. Medication usage behavior will be observed for 6 months, while documentation behavior on the wellness…
- Trial name
- PROmyBETAapp (NCT03134573)
- Testing
- Interferon beta-1b (Betaferon, BAY86-5046), Betaconnect auto-injector, myBETAapp
- Where
- Germany
- Volunteers
- 96 people
- Sponsor
- Bayer
Rheumatoid Arthritis, Psoriatic Arthritis
Therapeutic Strategy Associated With bDMARDs or tsDMARDs in Rheumatoid Arthritis and Psoriatic Arthritis
This is a longitudinal, observational, prospective, multicentre study conducted in France, among a representative sample of rheumatology doctors.
- Trial name
- STRATEGE2 (NCT05082805)
- Where
- France
- Volunteers
- 400 people
- Sponsor
- Nordic Pharma SAS
Dermatitis, Atopic
Protopic Ointment in Adult Atopic Eczema of the Face
Patients with facial atopic eczema and a poor response to topical corticosteroid applied either Protopic or Fluticasone ointment twice a day for 3 weeks.
- Trial name
- NCT00690105
- Testing
- tacrolimus 0.1%, fluticasone 0.005 %
- Where
- France
- Volunteers
- 577 people
- Sponsor
- Astellas Pharma Inc
High-risk Myelodysplastic Syndromes, Acute Myelogenous Leukemia
GTB-3550 Tri-Specific Killer Engager (TriKE®) for High Risk Hematological Malignancies
This is a multi-center Phase I/II clinical trial of GTB-3550 (CD16/IL-15/CD33) tri-specific killer cell engager (TriKE®) for the treatment of CD33-expressing high risk myelodysplastic syndromes, refractory/relapsed acute myeloid…
- Conditions
- High-risk Myelodysplastic Syndromes, Acute Myelogenous Leukemia, Systemic Mastocytosis, Mast Cell Leukemia
- Trial name
- NCT03214666
- Testing
- GTB-3550 TriKE® Phase I, GTB-3550 TriKE® Phase II
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- GT Biopharma, Inc.
Cold Agglutinin Disease
A Study to Assess the Efficacy and Safety of BIVV009 (Sutimlimab) in Participants With Primary Cold Agglutinin Disease Without A Recent History of Blood Transfusion
The purpose of Part A was to determine whether sutimlimab administration resulted in a greater than or equal to (>=)1.5 grams per deciliter (g/dL) increase in hemoglobin (Hgb) level and avoidance of transfusion in participants…
- Trial name
- Cadenza (NCT03347422)
- Testing
- sutimlimab (BIVV009)
- Where
- 53 sites in United States, Australia and 12 more
- Volunteers
- 42 people
- Sponsor
- Bioverativ, a Sanofi company
Juvenile Idiopathic Arthritis
A Study of Tocilizumab in Chinese Participants With Systemic Juvenile Idiopathic Arthritis (sJIA)
This Phase IV, multicenter, single-arm, open-label study will evaluate the efficacy and safety of tocilizumab in Chinese participants with sJIA with persistent activity and an inadequate response to non-steroidal…
- Trial name
- NCT03301883
- Testing
- Tocilizumab, NSAIDs, CSs
- Where
- 10 sites in China
- Volunteers
- 62 people
- Sponsor
- Hoffmann-La Roche
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.